Meet Our Team
Ranvier brings together scientists, clinicians, designers, and strategists with one mission: to revolutionise how we diagnose and treat mental and neurological conditions.
At the heart of our platform is the pioneering work of Dr David Adams, a clinician whose research led to the invention of our patented taste-based diagnostic and multimodal inference system. His vision - to replace guesswork with measurable biological and sensory signals - powers everything we do.
Our team has deep roots in diagnostics, digital health, and system innovation. We’re guided by world-class neurologists, psychiatrists, and AI experts. Our work is evidence-based, empathy-led, and built to scale.
We believe faster diagnoses mean better outcomes, and that recovery should be personal and accessible to all.
Development Pathway
2025
Capital Raise and platform development
Ranvier is raising capital to accelerate development of its diagnostic platform for depression and neurodegenerative disease. Funding will expand TasteDX™ and BioDX™, grow clinical and technical teams, and support regulatory progress. This raise enables scale-up and integration of multimodal data into our inference engine—advancing our goal to shift brain health care from reactive to preventative.
2022 - 2023
NHIR Extended Study
Ranvier participated in an NIHR-backed extended study to validate TasteDX™ as an objective diagnostic for mood disorders. The study evaluated accuracy, repeatability, and alignment with clinical standards across a broader population. Conducted with NHS and academic partners, the research marked a key milestone toward regulatory approval and clinical integration of Ranvier’s novel mental health technologies.
2021
Post COVID testing with Pharmacies
Following the COVID-19 pandemic, Ranvier partnered with pharmacies to deliver TasteDX™ as a frontline mental health screening tool. The program provided accessible testing in community settings, helping identify depression and anxiety without requiring specialist referral. It demonstrated the value of low-cost, objective diagnostics in post-pandemic care and supported better triage within strained health systems.